A Study of Secondary Infusion of Relmacabtagene Autoleucel Injection for Relapsed or Refractory B-cell Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorChanghai Hospital
About this trial
To evaluate the efficacy and safety of post-marketing Regiorense injection secondary infusion in the treatment of adult patients with relapsed or refractory B-cell lymphoma.
Eligibility criteria
Qualifiers
Informed Consent Form (ICF) was obtained from the patients.
Diagnosed relapsed or refractory B-cell lymphomas
diffuse large B-cell lymphoma-not otherwise specified
diffuse large B-cell lymphoma transformed from follicular lymphoma
Disqualifiers
Patients with hypersensitivity to the active ingredient or any excipients (dimethyl sulfoxide, compound electrolyte injection, human serum albumin);
Patients had uncontrolled systemic fungal, bacterial, viral, or other infections
Trial design
Treatments tested in this trial
- Relmacabtagene Autoleucel Injection
Treatment groups
13 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov